Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
THRX > SEC Filings for THRX > Form 8-K on 9-Jan-2014All Recent SEC Filings

Show all filings for THERAVANCE INC



Other Events, Financial Statements and Exhibits

Item 8.01 Other Events.

On January 9, 2014, GlaxoSmithKline plc (GSK) and Theravance, Inc. issued a press release announcing that ANORO™ ELLIPTA™ was approved in Canada on December 23, 2013 for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ANORO™ ELLIPTA™ (umeclidinium / vilanterol) dry powder for oral inhalation is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA). ANORO™ ELLIPTA™ combines two bronchodilators in a single inhaler for the maintenance treatment of COPD. It contains umeclidinium (UMEC), a LAMA and vilanterol (VI), a LABA. The approved dosage of ANORO™ ELLIPTA™ in Canada is 62.5/25mcg. UMEC/VI has been developed under the LABA collaboration agreement between Glaxo Group Limited and Theravance, Inc. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Description

Exhibit 99.1 Press Release dated January 9, 2014

  Add THRX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for THRX - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.